U.S. Markets closed

BioLine Rx Ltd (BLRX)


NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
0.851-0.02 (-2.30%)
At close: 3:59PM EDT
People also watch
CANFCPRXPLXAVEOANTH

BioLine Rx Ltd

Modi’in Technology Park
2 HaMa’ayan Street
Modi’in 7177871
Israel
972 8 642 9100
http://www.biolinerx.com

Sector
Industry
Full Time Employees43

Key Executives

NameTitlePayExercisedAge
Mr. Philip A. Serlin CPA, MBAChief Exec. Officer378kN/A57
Ms. Mali Zeevi CPAChief Financial Officer186kN/A41
Mr. David Malek MBAChief Bus. Officer297kN/A39
Advocate Norman KotlerInternal Enforcement Officer, Gen. Counsel and Corp. Sec.N/AN/A65
Raziel FriedBudget Control Mang. and TreasurerN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a novel peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immunotherapy treatment in development for multiple solid tumors; and BL-5010, a customized, proprietary, pen-like applicator containing a novel, acidic, aqueous solution as a medical device for the non-surgical removal of benign skin lesions. The company’s other therapeutic candidates comprise BL-1040, a novel, resorbable polymer solution for use in the prevention of ventricular remodeling that may occur in patients who have suffered an acute myocardial infarction; BL-9020, which is a novel monoclonal antibody treatment designed to prevent immune-mediated destruction of insulin-producing beta cells in the pancreas; BL-1210, a drug candidate intended for the treatment of liver fibrosis, primarily non- alcoholic steatohepatitis; BL-1220, an orally administered, novel composition of sodium alginate intended as a novel treatment for various liver failure conditions; and BL-1230, a cannabinoid receptor type 2 intended as a novel anti-inflammatory treatment for dry eye syndrome. The company has strategic collaborations with Novartis Pharma AG; Merck; MD Anderson Cancer Center to investigate the combination of BL-8040 with Keytruda (pembrolizumab) in pancreatic cancer; Genentech Inc. to investigate the combination of BL-8040 and Genentech’s Atezolizumab in various Phase Ib studies for multiple solid tumor indications and acute myeloid leukemia. BioLineRx Ltd. was founded in 2003 and is headquartered in Modi’in, Israel.

Corporate Governance

BioLine Rx Ltd’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.